CN111334475B - Application of INSRR gene, and product and method for regulating and controlling granulosa cells - Google Patents
Application of INSRR gene, and product and method for regulating and controlling granulosa cells Download PDFInfo
- Publication number
- CN111334475B CN111334475B CN202010177694.1A CN202010177694A CN111334475B CN 111334475 B CN111334475 B CN 111334475B CN 202010177694 A CN202010177694 A CN 202010177694A CN 111334475 B CN111334475 B CN 111334475B
- Authority
- CN
- China
- Prior art keywords
- gene
- insrr
- regulating
- granulosa cells
- granulosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002503 granulosa cell Anatomy 0.000 title claims abstract description 125
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000001276 controlling effect Effects 0.000 title claims abstract description 18
- 101150068197 INSRR gene Proteins 0.000 title abstract description 91
- 230000014509 gene expression Effects 0.000 claims abstract description 73
- 230000006907 apoptotic process Effects 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 241001494479 Pecora Species 0.000 claims description 27
- 230000033228 biological regulation Effects 0.000 claims description 27
- 230000002222 downregulating effect Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- 108020004459 Small interfering RNA Proteins 0.000 claims description 11
- 230000003828 downregulation Effects 0.000 claims description 6
- 210000004565 granule cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 abstract description 27
- 239000005556 hormone Substances 0.000 abstract description 27
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 abstract description 24
- 101150105763 FSHR gene Proteins 0.000 abstract description 20
- 210000004027 cell Anatomy 0.000 abstract description 19
- 101150114872 lhr gene Proteins 0.000 abstract description 18
- 238000002360 preparation method Methods 0.000 abstract description 8
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract description 6
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 abstract 1
- 239000000047 product Substances 0.000 description 51
- 230000028327 secretion Effects 0.000 description 37
- 108010059616 Activins Proteins 0.000 description 31
- 102000005606 Activins Human genes 0.000 description 31
- 239000000488 activin Substances 0.000 description 31
- 239000000893 inhibin Substances 0.000 description 30
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 30
- 108010014612 Follistatin Proteins 0.000 description 25
- 102000016970 Follistatin Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 230000008217 follicular development Effects 0.000 description 21
- 238000011161 development Methods 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 108010054372 insulin receptor-related receptor Proteins 0.000 description 16
- 210000000287 oocyte Anatomy 0.000 description 16
- 101150034559 IGF1R gene Proteins 0.000 description 14
- 102100039137 Insulin receptor-related protein Human genes 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 210000001672 ovary Anatomy 0.000 description 14
- 108010004250 Inhibins Proteins 0.000 description 12
- 102000002746 Inhibins Human genes 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 230000003325 follicular Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000006408 female gonad development Effects 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 5
- 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 description 5
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 102000006771 Gonadotropins Human genes 0.000 description 4
- 108010086677 Gonadotropins Proteins 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 102000003746 Insulin Receptor Human genes 0.000 description 4
- 108010001127 Insulin Receptor Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- 206010042573 Superovulation Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000002622 gonadotropin Substances 0.000 description 4
- 102000014650 luteinizing hormone receptor activity proteins Human genes 0.000 description 4
- 108040006978 luteinizing hormone receptor activity proteins Proteins 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 102100029951 Estrogen receptor beta Human genes 0.000 description 3
- 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000008182 oocyte development Effects 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108010069241 Connexin 43 Proteins 0.000 description 2
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 2
- 101150106864 HR gene Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004584 Somatomedin Receptors Human genes 0.000 description 2
- 108010017622 Somatomedin Receptors Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010015408 connexin 37 Proteins 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 210000000799 primary oocyte Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108010060374 FSH Receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018343 Follicle stimulating hormone receptors Human genes 0.000 description 1
- 101710190724 Gap junction alpha-4 protein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000023752 cell cycle switching, mitotic to meiotic cell cycle Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000028315 developmental maturation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- -1 kits Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000024717 negative regulation of secretion Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
The invention providesAn INSRR gene application, a product for regulating and controlling granular cells and a method, which relate to the technical field of biology. The application of the INSRR gene in the preparation of products for regulating granulosa cells and products and methods for regulating granulosa cells include regulating granulosa cell apoptosis, regulating the expression of at least one of the granulosa cell LHR gene, FSHR gene, ER β gene and IGF1R, and regulating at least one of the granulosa cell secreted hormones; wherein the hormone comprises E2、P4At least one of ACT, INH, and FS.
Description
Technical Field
The invention relates to the technical field of biology, in particular to application of an INSRR gene, a product for regulating and controlling granulosa cells and a method.
Background
Follicular development is mainly regulated by reproductive hormones, gonadotropins are the main signals for ovarian development, and they act on the ovaries through the blood circulation system to produce gonadal hormones. A large number of primordial follicles accumulate in the ovaries after formation, and only a few dominant follicles can develop to preovulatory large follicles under the action of Follicle Stimulating Hormone (FSH). The preovulatory large follicles produce large amounts of E2And in the absence of the corpus luteum, causes a Luteinizing Hormone (LH) spike to occur, resulting in ovulation.
Primordial follicles are formed by the transformation of oocytes to approximately 20-35mm in diameter by the cessation of mitosis and entry into meiosis. Each primordial follicle is composed of a primary oocyte and several granulosa cells that surround the oocyte in polar form and suppress the primordial follicle recruitment process by secreting anti-mullerian hormone.
After primordial follicle is initially recruited, the primordial granulosa cells change from flat to cubic or high columnar shape, then the oocyte genome is activated, the granulosa cells express follicle stimulating hormone receptors, and the oocytes grow and differentiate. In mice, it was found that kit ligands produced by granulosa cells can promote oocyte growth. After follicle recruitment, the oocyte will express Connexin 37(Connexin 37, Cx37) to form gap links for completing the transfer of substances between granulocytes and oocyte through the link, providing the necessary nutritional and regulatory signals for oocyte maturation.
Secondary follicular development begins with the appearance of a second layer of granulosa cells. The oocyte regulates the proliferation of cumulus cells and granulosa cells, the synthesis and secretion of steroid hormones, and thus inhibits the luteinization of the oocyte. At the secondary follicular stage, follicular cells emerge, which begin to express receptors for gonadotropins with granulosa cells. Gap junction protein 43(Connexin 43, Cx43) which plays an essential role in regulating secondary follicular formation is also expressed on granulosa cells. As granulosa cells differentiate, the diameter of the follicle gradually increases, with decreasing levels of Activin (ACT) and increasing levels of Inhibin (Inhibin, INH) in the follicle. In the glaff follicle, granulosa cells differentiate into parietal granulosa cells, periluminal granulosa cells, cumulus cells and radiocorona cells.
At follicle maturation, the volume reaches a maximum, the follicular fluid is at a maximum, and the follicular wall also thins, the follicle at this time being called mature follicle. The number of follicles developing side by side to mature follicles is not constant, may be multiple, or may be only one, depending mainly on whether the animal is a multiparous animal or a single-born animal. The changes in the follicles during this period are absolutely dependent on gonadotropin secretion.
It can be seen that granulosa cells and their associated hormone secretion provide sufficient physical and chemical conditions for oocyte development, and are crucial for supporting oocyte developmental maturation, the transmission of endocrine, i.e. other environmental signals. Therefore, the development of a regulation method for regulating granulosa cells and products thereof has an important role in understanding the physiological and biochemical functions of granulosa cells and follicles.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The first purpose of the invention is to provide the application of INSRR gene in preparing products for regulating and controlling granulosa cells, so that the prepared products for regulating and controlling granulosa cells have at least one function of regulating and controlling granulosa cell apoptosis, hormone secretion and gene expression.
It is a second object of the invention to provide a product for the modulation of granulosa cells.
The third purpose of the invention is to provide a regulation method of granular cells.
The fourth purpose of the invention is to provide the product for regulating the granular cells or the application of the regulation method of the granular cells.
In order to solve the technical problems, the invention adopts the following technical scheme:
according to one aspect of the invention, there is provided the use of the INSRR gene in the manufacture of a product for the regulation of granulosa cells; the regulatory particle cells include: regulating at least one of granulosa cell apoptosis, regulating expression of granulosa cell genes, and regulating secretion of hormones by granulosa cells;
the regulating the expression of granulosa cell genes comprises regulating at least one of LHR gene, FSHR gene, ER β gene and IGF 1R; the hormone comprises E2、P4At least one of ACT, INH, and FS.
According to another aspect of the invention there is also provided a product for the regulation of granulosa cells comprising a substance for over-expressing the INSRR gene and/or a substance for inhibiting the expression of the INSRR gene.
According to another aspect of the invention, there is also provided a method of modulating granulosa cells, the method comprising up-regulating or down-regulating the expression of the INSRR gene in the granulosa cells.
According to another aspect of the present invention, the present invention also provides the use of the product for regulating granulosa cells or the regulation method of granulosa cells in at least one of the following (x1) to (x 4);
(x1) regulating follicular development;
(x2) regulating ovarian development;
(x3) preparing a product for regulating follicular development;
(x4) preparing a product for regulating ovarian development.
Compared with the prior art, the invention has the following beneficial effects:
based on the regulation effect of the INSRR gene on the granulosa cells found in the experiment, the invention provides application of the INSRR gene in preparation of products for regulating the granulosa cells, a regulation method of the granulosa cells and application of the INSRR gene and the products.
Experiments show that the INSRR gene can promote apoptosis of granulosa cells; the INSRR gene is also related to the expression of LHR gene, FSHR gene, ER beta gene and IGF1R gene in granulosa cells, and can inhibit the expression of LHR gene, FSHR gene and ER beta gene and promote the expression of IGF1R gene. Experiments show that the INSRR gene can regulate and control the secretion of hormones of granulocytes, wherein the hormones mainly comprise estradiol (E)2) Progesterone (P)4) Activin (ACT), Inhibin (INH) and Follistatin (FS), the INSRR gene promotes E2、P4And secretion of ACT, inhibiting secretion of INH and FS.
Based on the regulation effect of the INSRR gene on the granulosa cells, the regulation method of the granulosa cells and the product for regulating the granulosa cells can effectively regulate apoptosis of the granulosa cells and regulate secretion of reproductive hormone related to follicular development. Meanwhile, based on the regulation and control effect of the granulosa cells on the development of the follicle and the ovary, the regulation and control method of the granulosa cells and the product for regulating and controlling the granulosa cells can be further applied to the regulation and control of the development of the follicle and the ovary or used for preparing the product for regulating and controlling the development of the follicle and the ovary, the regulation and control effect on the follicle and/or the ovary in vivo or in vitro is realized, and the method and the guarantee of the product are provided for the research on the development and physiological and biochemical functions of the granulosa cells, the follicle and the ovary.
The method for regulating and controlling the granulosa cells, provided by the invention, is used for regulating and controlling the products of the granulosa cells and the application of the products, can deepen the understanding of the maturation mechanism of the oocytes at the later stage of follicular development, further excavate factors related to follicular development, perfect signal paths related to follicular development, disclose the mechanism of follicular development and optimize an oocyte in-vitro culture system. The method has important significance in further carrying out superovulation of mammals, embryo in-vitro production, multi-fetus variety breeding and the like.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 shows the relative expression level of INSRR gene following transfection of granulosa cells with siRNA in example 1 of the present invention;
FIG. 2 shows the detection result of apoptosis in flow cells after INSRR gene interference in example 2 of the present invention;
FIG. 3 is a graph showing the rate of granulosa cell apoptosis following INSRR gene interference in example 2 of the present invention;
FIG. 4 is a graph showing the proliferation rate of granulosa cells after interference of the INSRR gene in example 2 of the present invention;
FIG. 5 is a graph showing the effect of INSRR gene interference on sheep granulosa cell gene expression in example 3 of the present invention;
FIG. 6 shows the effect of INSRR gene on ovine granulosa cell E after disruption in example 4 of the present invention2The effect of secretion;
FIG. 7 shows the interaction of INSRR gene on ovine granulosa cells P in example 4 of the present invention4The effect of secretion;
FIG. 8 is a graph showing the effect of interference of the INSRR gene on the secretion of ACT by sheep granulocytes in example 4 of the present invention;
FIG. 9 is a graph showing the effect of interference of the INSRR gene on INH secretion from sheep granulocytes in example 4 of the present invention;
FIG. 10 is a graph showing the effect of interference of the INSRR gene on FS secretion in sheep granulocytes in example 4 of the present invention.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments, and it should be understood that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
According to one aspect of the invention there is provided the use of an INSRR gene in the manufacture of a product for regulating granulosa cells, wherein regulating granulosa cells comprises regulating at least one of granulosa cell apoptosis, regulating expression of a granulosa cell gene, and regulating secretion of hormones by granulosa cells. The regulating the expression of granulosa cell genes comprises regulating at least one of LHR gene, FSHR gene, ER β gene and IGF 1R; the hormone comprises E2、P4At least one of ACT, INH, and FS.
Insulin Receptor-Related Receptor (INSRR) genes encode Insulin Receptor-Related receptors (IRRs), which belong to the Insulin Receptor family, which belongs to the RTK type ii subfamily of the Receptor tyrosine kinase family (RTKs), which further comprises Insulin Receptors (IR), Insulin-like growth factor receptors (IGF-R), which activate intracellular tyrosine kinases upon binding to respective ligands, such as Insulin, Insulin-like growth factors (IGF-1 or IGF-2), initiating intracellular signaling to exert physiological functions in organisms. At present, the function research of insulin receptor related receptor (IRR) is less, and experiments show that INSRR gene is related to apoptosis of granulosa cells and can promote the granulosaApoptosis of the cell; the INSRR gene is also related to the expression of LHR, FSHR and ER β genes related to oocyte development in granulocytes, and can inhibit the expression of LHR, FSHR and ER β genes; the INSRR gene is also involved in the expression of the IGF1R (insulin-like growth factor 1 receptor) gene in granulosa cells, and is capable of promoting the expression of the IGF1R gene. Experiments show that the INSRR gene can regulate and control the secretion of hormones of granulocytes, wherein the hormones mainly comprise estradiol (E)2) Progesterone (P)4) Activin (ACT), Inhibin (INH) and Follistatin (FS), the INSRR gene promotes E2、P4And secretion of ACT, inhibiting secretion of INH and FS.
Granulosa cells of mature follicles are the largest group of cells that make up follicles, and during follicular development, the proliferation, differentiation, and apoptosis of granulosa cells play an important role in the development and maturation of oocytes. Studies have shown that if follicular apoptosis of granulosa cells during development leads to follicular atresia, the pregnancy rate after embryo transfer is higher with a low rate of granulosa cell apoptosis in vitro fertilization.
The hormone secreted by granulosa cells also plays an important role in the growth and development of follicles and ovaries. For example, Inhibin (INH) secreted by granulosa cells has the functions of regulating follitropin and stimulating androgen secretion from ovarian follicular membranes; the Activin (ACT) secreted by the granulosa cells is involved in the development of early follicles, is related to the atresia of mature follicles, and has the effects of promoting the maturation of the follicles and enhancing the functions of the granulosa cells; after the Follistatin (FS) secreted by granulosa cells is combined with ACT, the follicular atresia of ACT can be prevented, and the follicle can be promoted to continue to grow and mature. Meanwhile, the roles played by INH and ACT in follicular development are opposite, with the level of ACT in the follicles decreasing as granulosa cells differentiate, while INH gradually increases. Estradiol secreted by granulosa cells (E)2) And progesterone (P)4) It is also a reproduction-related hormone with multiple effects, and has multiple effects on ovarian development.
Each primordial follicle is composed of a primary oocyte and several granulosa cells. The follicular development is mainly regulated by reproductive hormone, gonadotropin is a main signal for ovarian development, a large number of primordial follicles are formed and gathered on ovaries, and develop to preovulatory large follicles under the regulation of Follicle Stimulating Hormone (FSH), and the preovulatory large follicles generate a large amount of E2And in the absence of the corpus luteum, promotes the appearance of an LH surge, resulting in ovulation. IGF1R promotes the continued development of luminal follicles, which has an effect on FSHR expression and estradiol synthesis, leading to impaired granulosa cell proliferation and arrest in follicular development. It can be seen that in organisms, the generation and development of follicles are completed by the cooperation of a plurality of factors, and the expression of LHR, FSHR, ER beta and IGF1R on granulosa cells is regulated, so that a good basis is provided for further research on the development mechanism of follicles and control of the development of follicles and ovaries.
Based on the functions of the INSRR gene provided by the invention, the INSRR gene provided by the invention is applied to preparation of a product for regulating granulosa cells, and the product at least adopts up-regulation or down-regulation of the expression level of the INSRR gene to realize the regulation effect on the granulosa cells.
In some alternative embodiments, the product achieves at least one of the following regulatory effects by up-regulating the expression of the INSRR gene: inhibiting granular cell apoptosis; up-regulating IGF1R gene expression level; down-regulating the expression level of at least one of LHR gene, FSHR gene and ER beta gene; promotion of E2、P4And secretion of at least one of ACT; and, inhibiting secretion of at least one of INH and FS.
In some alternative embodiments, the product down-regulates the expression of the INSRR gene to achieve at least one of the following regulatory effects: promoting granular cell apoptosis; down-regulating the expression level of IGF1R gene; up-regulating the expression level of at least one of LHR gene, FSHR gene and ER beta gene; inhibition of E2、P4And secretion of at least one of ACT; and, promoting secretion of at least one of INH and FS.
It will be appreciated that the product is not limited to effecting up-regulation or down-regulation of the INSRR gene, but also up-regulation and/or down-regulation of the expression of other genes to effect modulation of other hormones, gene expression or other physiological and biochemical activities in the granulosa cells. The product regulates and controls granular cells, and can be regulated and controlled in vivo or in vitro.
In the above examples, when the product is used for regulating the expression of genes in granulosa cells, the product can simultaneously regulate the expression of the HR gene, FSHR gene, ER β gene and IGF 1R; it is also possible to regulate the expression of only one, two or three of the genes: for example, but not limited to, the product contains a substance for overexpressing the INSRR gene and a substance for overexpressing at least one of the LHR gene, the FSHR gene and the ER beta gene, and the product can realize the function of up-regulating the expression level of IGF1R gene and simultaneously generating no inhibition effect on at least one of the LHR gene, the FSHR gene and the ER beta gene.
In the above examples, when the product is used to promote or inhibit E2、P4Secretion of at least one of ACT, INH and FS, and the product can regulate the five hormones at the same time or only one, two, three or four of the hormones. For example, the product contains a substance which inhibits the expression of the INSRR gene, together with a substance which promotes E2、P4And ACT, which can promote secretion of INH and FS while inhibiting E alone2、P4And some hormones in ACT, or not E2、P4And a function of inhibiting secretion of ACT.
Use of the INSRR gene in the preparation of a product for regulating granulosa cells may, in some alternative embodiments, be achieved by including in the product a substance capable of up-regulating and/or down-regulating the INSRR gene. For example, but not limited to, the INSRR gene may be used by at least one of the following ways: down-regulating expression of a gene by containing an siRNA capable of interfering with expression of the gene, or expressing DNA of the siRNA; overexpression of the gene is achieved by a recombinant vector containing the gene expressing INSRR; regulating and controlling a gene by a protein or a compound drug or the like capable of inhibiting the expression of a target gene; the gene is regulated by containing cells or microorganisms capable of expressing the gene having the function of regulating the expression of the gene.
In some alternative embodiments, the INSRR gene used in the preparation of a product for regulating granulosa cells comprises the sequence shown in SEQ ID No. 1; or a sequence having at least 90% homology with the sequence shown in SEQ ID NO. 1. Wherein a sequence having more than 90% homology refers to a sequence which is not completely identical to a target sequence due to deletion, insertion or change of nucleotides, but has at least 90% similarity and has the same function as the target sequence. Sequences with more than 90% homology to the rest of the text are likewise understood.
In the above embodiments, "comprising" means that the gene may contain, in addition to a sequence having a sequence as shown in SEQ ID NO.1 or having 90% or more homology with SEQ ID NO.1, other functional units such as one or more of a promoter, a terminator, an enhancer and a transcription factor binding region; may also contain sequences encoding one or more of markers, tags and resistance genes; vector sequences and the like can also be included; or cDNA of the gene with the sequence shown in SEQ ID NO.1 or with more than 90 percent of homology with SEQ ID NO. 1. The other genes "comprising" as shown in the sequence listing are also understood in the same way and are not described in detail.
Based on the inventive concept of the application of the INSRR gene in the preparation of products for regulating granulosa cells, the invention also provides a product for regulating granulosa cells, wherein the product comprises a substance for over-expressing the INSRR gene and/or a substance for inhibiting the expression of the INSRR gene, and the regulation of granulosa cells is realized by regulating the expression of the INSRR gene.
The product for regulating and controlling the granular cells provided by the invention comprises but is not limited to reagents, kits, medicaments or culture media and the like. The product may achieve regulation of the INSRR gene by comprising a substance capable of up-regulating the INSRR gene and/or down-regulating the INSRR gene. The substances in the product for up-regulating the INSRR gene and down-regulating the INSRR gene respectively and independently comprise at least one of DNA, RNA, protein, polypeptide, compound drugs, cells and microorganisms. Examples may include, but are not limited to: siRNA, in order to interfere INSRR gene expression, play the role in lowering INSRR gene expression, said siRNA preferably contains as shown in SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4, more preferably contains as shown in SEQ ID NO.4 sequence; a plasmid expressing the siRNA; a cell or recombinant microorganism containing said siRNA or said plasmid; a vector, such as a DNA plasmid or viral vector, capable of expressing the INSRR gene to achieve overexpression of the INSRR gene; a polypeptide or protein capable of promoting or inhibiting the INSRR gene, such as a transcription factor or an inhibitor of a transcription factor; compounds that promote or inhibit the INSRR gene, such as inhibitors or agonists that interfere with the signaling pathway of INSRR gene expression.
Based on the regulatory effect of the INSRR gene on granulosa cells found in the present invention, the present invention also provides a method for regulating granulosa cells, comprising up-regulating or down-regulating the expression of the INSRR gene in granulosa cells. The regulation of granulosa cells according to the present invention includes the following aspects: regulating granular cell apoptosis; regulating expression of granulosa cell genes, the regulated genes including at least one of IGF1R gene, LHR gene, FSHR gene, and ER β; regulating secretion of hormones by granulosa cells, said hormones including E2、P4At least one of ACT, INH and FS. The regulation method of the granular cells can be realized by at least one of the following embodiments:
in some alternative embodiments, the expression level of the INSRR gene is up-regulated to achieve at least one of the following regulatory effects: inhibiting granular cell apoptosis; up-regulating IGF1R gene expression level; down-regulating the expression level of at least one of LHR gene, FSHR gene and ER beta gene; promotion of E2、P4And secretion of at least one of ACT; and, inhibiting secretion of at least one of INH and FS.
In some alternative embodiments, the expression level of the INSRR gene is downregulated such that at least one of the following regulatory effects is achieved: promoting granular cell apoptosis; down-regulating the expression level of IGF1R gene; up-regulating the expression level of at least one of LHR gene, FSHR gene and ER beta gene;inhibition of E2、P4And secretion of at least one of ACT; and, promoting secretion of at least one of INH and FS.
It should be noted that the present invention is not limited to regulating the expression of the INSRR gene in the granulosa cell and simultaneously regulating the expression of other genes in the granulosa cell, so as to achieve regulation of other genes, hormones, or other physiological and biochemical activities in the granulosa cell.
In the above examples, the regulation and control method can simultaneously regulate and control the expression of the HR gene, FSHR gene, ER β gene and IGF1R when regulating and controlling the expression of the genes in the granulosa cells; it is also possible to regulate the expression of only one, two or three of the genes: for example, but not limited to, the method may be a method for down-regulating the expression of the INSRR gene and simultaneously down-regulating at least one of the LHR gene, FSHR gene and ER β gene, so as to achieve down-regulation of the expression level of IGF1R gene without changing the expression level of one or more of the LHR gene, FSHR gene and ER β gene.
In the above examples, the modulation method is used to promote or inhibit E2、P4Secretion of at least one of ACT, INH and FS may be regulated simultaneously or only one, two, three or four of these hormones. For example, but not limited to, it may be desirable to up-regulate the expression of the INSRR gene to promote E2、P4And secretion of ACT, while up-regulating genes that promote secretion of INH and FS, to avoid inhibition of secretion of INH and FS.
In some alternative embodiments, the INSRR gene used in the preparation of a product for regulating granulosa cells comprises the sequence shown in SEQ ID No. 1; or a sequence having at least 90% homology with the sequence shown in SEQ ID NO. 1.
Based on the proliferation, differentiation and apoptosis of granulosa cells and the development effect of hormones on follicles and ovaries, the regulation method of granulosa cells provided by the invention or the product for regulating granulosa cells can also be applied to the following aspects: (x1) regulating follicular development; (x2) regulating ovarian development; (x3) preparing a product for regulating follicular development; (x4) preparing a product for regulating ovarian development. By obtaining the method or the product for regulating and controlling the granulosa cells, the follicles and the ovaries, the understanding of the maturation mechanism of the oocytes at the later stage of follicular development is deepened, for example, the method for regulating and controlling the granulosa cells provided by the application interferes with the development of the granulosa cells, the follicular development can be indirectly controlled, and a technical guarantee is provided for the maturation matrix of the follicles; by regulating the expression of genes or hormones in granulosa cells through the regulating method or the product, factors related to follicular development can be further excavated, a signal path related to follicular development is perfected, and a mechanism of follicular development is disclosed. As the granular cells play a key role in the development of follicles, the regulation and control of the granular cells can optimize an oocyte in-vitro culture system, have important significance in the development of superovulation of mammals, embryo in-vitro production, multi-fetus variety breeding and the like, and provide technical and material guarantee for livestock breeding and the screening of livestock with excellent fertility.
The invention is not limited to the use of the INSRR gene in the preparation of products for the regulation of granulosa cells, methods of regulation of granulosa cells and the sources of granulosa cells, follicles and ovaries involved in their use, examples of sources including, but not limited to, one or more of cattle, horses, cows, pigs, sheep, goats, rats, mice, dogs, cats, rabbits, camels, donkeys, deer, mink and humans.
In some alternative embodiments the INSRR gene comprises the sequence shown in SEQ ID NO. 1; or, the sequence containing at least more than 90% homology with the sequence shown in SEQ ID NO.1 is derived from sheep, so that the sources of granulosa cells, follicles and ovaries are also corresponding to the optimized sheep, which has important significance for further carrying out sheep superovulation, lamb superovulation, sheep embryo in-vitro production, multiparous sheep variety breeding and the like, and is beneficial to the development of sheep breeding industry.
The technical solution and the advantages of the present invention will be further explained with reference to the preferred embodiments. The experimental methods used in the examples of the present invention are all conventional experimental methods in molecular biology, and can be performed according to conventional molecular biology experimental manuals or kit instructions.
Example 1
INSRR gene siRNA interference:
3 pairs of interference fragments are designed aiming at the INSRR gene of sheep, the three pairs of fragments respectively and independently contain sequences shown in SEQ ID NO. 2-4 in sequence, and 3' ends respectively and independently overhang unpaired TT is shown as follows:
INSRR siRNA-1(968):5’-CCAACCACAUUGUGGGCAAtt-3’(SEQ ID NO.5);
INSRR siRNA-2(1988):5’-GCAUCAACUUGGAGUACUUtt-3’(SEQ ID NO.6);
INSRR siRNA-3(3720):5’-CCUUGCUGCCAACAAGUUUtt-3’(SEQ ID NO.7)。
the relative INSRR expression levels after 3 pairs of interfering fragments were 65.82. + -. 3.57%, 69.87. + -. 3.56% and 46.44. + -. 3.70% of the blank, respectively, as shown in FIG. 1, and therefore, the 3 rd pair of interfering fragments were selected for subsequent cell transfection experiments.
"control" in FIG. 1 represents an untreated control group; "INSRR" represents the interfered group of INSRR genes. "siRNA-1" represents the INSRR gene siRNA-1 treated group; "siRNA-2" represents the INSRR gene siRNA-2 treated group; "siRNA-3" represents the INSRR gene siRNA-3 treated group. Data are presented as mean ± SEM, statistical analysis using t-test. Indicates significant difference, p < 0.05.
Example 2
Effect of INSRR gene on apoptosis and proliferation of sheep granulosa cells:
the apoptosis condition of sheep granulosa cells after INSRR gene interference is detected through flow apoptosis detection, and the result is shown in figure 2, wherein 'siINSRR' represents an INSRR gene siRNA interference treatment group, and 'control' represents an untreated control group, and the INSRR gene interference group granulosa cell apoptosis rate is 16.03 +/-0.54% and is remarkably higher than that of a blank control group (6.98 +/-0.07%).
The MTT method is used for detecting the sheep granulosa cell proliferation rate after INSRR gene interference, and the results are shown in fig. 3 and 4, wherein the cell proliferation rate after INSRR gene interference is not obviously changed. "control" in FIGS. 3 and 4 represents an untreated control group; "INSRR" represents the interfered group of INSRR genes. Data are presented as mean ± SEM, statistical analysis using t-test. Indicates significant difference, p < 0.05.
Example 3
And (3) detecting the gene expression quantity of LHR gene, FSHR gene and ER beta gene related to oocyte development in the sheep granulosa cell after INSRR gene interference. The INSRR gene was used as a receptor gene related to the insulin receptor, and the expression level of IGF1R gene was detected.
After INSRR gene interference is found, the expression level of IGF1R gene in granulosa cells is obviously reduced, and the expression levels of LHR gene, FSHR gene and ER beta gene related to follicular development are all obviously increased. It is shown that INSRR gene exerts inhibitory effect on expression of LHR gene, FSHR gene and ER beta gene in sheep granulosa cells, and expression level of IGF1R gene is also affected by interference of INSRR gene, as shown in FIG. 5.
"control" in FIG. 5 represents an untreated control group; "si-INSRR" represents the interference handling group. "IGF 1R" represents the expression level of IGF1R gene; "LHR" represents the expression level of LHR gene; "FSHR" represents the amount of FSHR gene expression; "ER β" represents the expression level of ER β gene; data are presented as mean ± SEM, statistical analysis using t-test. Indicates significant difference, p < 0.05.
Example 4
INSRR gene on sheep granulosa cell E2、P4Regulation of ACT, INH and FS secretion:
the supernatant in the pellet cell culture dish after the interference is subjected to E through an ELISA method2、P4ACT, INH and FS detection, as shown in fig. 6 to 10. Finding granulosa cells E2、P4And secretion of ACT decreased significantly, and secretion of INH and FS increased significantly. Indicates that the INSRR gene can play a function in the sheep ovarian granulosa cells and is used for E in the cells2、P4And ACT secretion, and has inhibitory effect on INH and FS secretion in sheep granulosa cells. "control" in FIGS. 6 to 10 represents an untreated control group; "INSRR" represents the interference handling group. Data are expressed as mean. + -. SEM, using t-testAnd (5) carrying out statistical analysis. Indicates significant difference, p < 0.05.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
SEQUENCE LISTING
<110> Jilin province academy of agricultural sciences
<120> application of INSRR gene, and product and method for regulating and controlling granulosa cells
<160> 7
<170> PatentIn version 3.5
<210> 1
<211> 3906
<212> DNA
<213> sheep (Ovis aries)
<400> 1
atggccgtgc ccagcctgtg gccctgggtg gcttgcctgc tggccgtgct gctgagcctg 60
ggctttgggc tggacacccg ggaggtgtgc ccctctctgg acatccgttc cgaagtggcc 120
gagctgcgca ggctcgagaa ctgttctgtg gtggaaggcc atctgcagat cctgctgatg 180
tttaccgcca ccggcgaaga ctttaggggc ctgagcttcc ccaggctgac ccaggtgacc 240
gactacctgc tgctgttccg cgtgtatggt ctggagtccc tgcgcgacct gttccccaac 300
ctggccgtga tccgcggcgc cagactgttc ctgggctacg ccctcgtgat ctttgagatg 360
ccccatatga gggacgtggg tctgcccgct ctgggcgctg tgctgcgtgg tgctgtgagg 420
gtggagaaga accaggagct gtgccatctc agcaccatcg actggggact gctgcagccc 480
agccccggag ctaaccatat cgtggggaac aaactggggg aggaatgtgc cgacgtgtgc 540
cccggactgc tcggcgctac cggagagcca tgcgccagga ccacctttag cggccatacc 600
gactaccgat gctggacctc tagccactgc cagaaggtgt gcccctgccc caggggtctc 660
gcctgtaccg tgaggggaga atgctgccat accgagtgcc tgggcggatg tagccgccct 720
gaggacccta gggcctgcgt ggcttgtagg catctgtact tccagggcgc atgtcataga 780
gcctgccctc caggcaccta ccagcacgaa agctggaggt gcgtgaccgc cgagaggtgt 840
gccagcctga gaagcgtgcc cggcagggct tccaccttcg gaatccatca gggcagctgt 900
ctggctcagt gtcctcccgg cttcacccgg aacgacagca gcatcttttg tcataagtgc 960
gagggcctgt gccctaaaga gtgcaaagtg ggcaccaaga ccatcgacag cgtgcaggcc 1020
gcccaggacc tggtgggatg tacccatgtg gagggaagcc tgatcctgaa cctgaggcag 1080
ggatataacc tcgagctgga gctgcagagg agcctgggcc tggtggaaac catcaccgga 1140
ttcctgaaaa tcaagcatag ctttgctctg gtgagtctcg gctttttcaa aaacctcaag 1200
ctgatcaggg gggacaccat ggtggacgga aactataccc tgtacgtgct ggacaaccag 1260
aacctgcagc agctcggcag ttgggtggct gccggcctga ccatccccgt gggaaaaatc 1320
tacttcgctt tcaaccccag gctgtgcctg gagcatatct accgcctcga ggaggtgacc 1380
ggcaccaaag gcaggcagaa caaggccgaa atcaaccccc gcaccaacgg cgaccgcgcc 1440
gcttgccaga ccagaaccct caggttcgtg agcaacgtga ccgaagccaa caggatcctg 1500
ctgaggtggg aaaggtacga acccctggag gccagggacc tgctgagttt tatcgtgtat 1560
tacaaggaga gccccttcca gaacgccacc gagtatgtgg ggcccgacgc ctgcggcgct 1620
cagagctgga acctgctgga cgtggagctg ccactgtcca ggacccagga gcccggcgtg 1680
accctggcac ctctgaaacc ctggacccag tacgccgtgt tcgtgagggc catcaccctc 1740
accaccgccg aagacagccc tcatcaggga gcccagagcc ccatcgtgta cctgcgcacc 1800
ctgcccgccg cccctaccgt gcctcaggac gtgatcagca ccagcaacag cagcagccac 1860
ctgctggtga gatggaagcc ccccatccag aggaacggca acatcaccta ctacctcgtg 1920
ctctggcagc gcctggctga ggacagcgac ctctacctga acgactactg ccacagaggc 1980
ctccgcctgc ccacctccaa caacgacccc cgcttcgacg gcgaagacgg cgaactggaa 2040
gccgacaggg aacccggatg ctgcccctgc cagcatccac cccccggaca ggtgctgccc 2100
cctctggaag cccaggaggc cagcttccag aaaaagttcg agaacttcct gcataacgcc 2160
atcaccatcc ccaagagccc ctggaaggtg accagcatca acaagagccc ccagcgcgac 2220
agcggaagga gcaggcgagc cgctgaggcc ctgaggctgg gaggtaacag cagcgacttc 2280
aaaatccagg aagacaaggt gccaagggaa agagcagtgc tgagcggcct gaggcatttc 2340
accgagtaca ggatcgacat ccatgcctgc aaccatgctg cacacaccgt gggatgcagc 2400
gccgccacct tcgtgtttgc caggaccatg ccccataggg aagctgacgg aatccccggc 2460
aaggtggcct gggaagcagc cagtaagagc tccgtgctgc tccgctggct ggagccccct 2520
gaccctaacg gtctgatcct gaagtacgag atcaaataca ggaggctggg cgaggaggca 2580
accgtgctgt gcgtgagtag gctgaggtac gctaaattcg gcggcgtgca tctggcactg 2640
ctgccacccg gcaactacag cgccagggtg agggccacca gcctggctgg aaacggaagc 2700
tggaccgaca gtgtggcatt ctacatcccc ggccccgagg aggaggactc cggaggactg 2760
catgtgctgc tgaccgtgac ccccgtggga ctgatgctgc tgatcatcct ggccgccctg 2820
ggctttttct attccaagaa gcgcaactcc accctgtatg ccagcgtgaa ccccgaatac 2880
ttctccgcct cccatatgta catccccgac gagtgggaag tgccccgcga acagatcagc 2940
atcatccgcg aactgggaca gggcagcttc ggcatggtgt acgagggcct ggcccagggc 3000
ctggaagtgg gagaggagcc cacccccgtg gctctgaaga ccgtgaacga gctggccagc 3060
cccagggaga ggatcgaatt tctgaaggaa gccagtgtga tgaaagcctt taaatgtcat 3120
catgtggtga ggctgctggg cgtggtgagt cagggacagc ccaccctggt gatcatggaa 3180
ctgatggcaa ggggagacct gaagagccat ctgaggagcc tgaggcccga ggccgaaaac 3240
aaccccggac tccccaggcc cgccctggga gacatgatcc agatggctgg cgagatcgct 3300
gacggaatgg cctacctggc cgccaacaaa ttcgtgcata gggacctggc cgcccgaaac 3360
tgcatggtga gccaggactt taccgtgaaa atcggcgact tcggaatgac cagggacgtg 3420
tatgagaccg actactaccg caaaggcggc aaaggactgc tgcccgtgag gtggatggct 3480
cccgagagcc tcaaggacgg catcttcacc acccatagcg acgtgtggag cttcggagtg 3540
gtgctgtggg agatcgtgac cctggctgag cagccctatc agggactgag caacgaacag 3600
gtgctgaaat tcgtgatgga cggcggagtg ctggaggagc tggagagctg tcctgtgcag 3660
ctgcaggagc tgatgcagag gtgttggcag cagaacccaa ggctgaggcc taccttcacc 3720
catatcctgg acagcatcca ggaggagctg aggcccagct ttaggctgct gagtttctac 3780
cattcccccg gctgcagagg tgctagggca tccctccccc ccaccgacgc tgagcctgac 3840
agccctagaa cccccaaaga ggccagcagc gactttagcc cccagaacgg cggccccggc 3900
cattag 3906
<210> 2
<211> 19
<212> RNA
<213> Artificial sequence
<400> 2
ccaaccacau ugugggcaa 19
<210> 3
<211> 19
<212> RNA
<213> Artificial sequence
<400> 3
gcaucaacuu ggaguacuu 19
<210> 4
<211> 19
<212> RNA
<213> Artificial sequence
<400> 4
ccuugcugcc aacaaguuu 19
<210> 5
<211> 21
<212> DNA
<213> Artificial sequence
<400> 5
ccaaccacau ugugggcaat t 21
<210> 6
<211> 21
<212> DNA
<213> Artificial sequence
<400> 6
gcaucaacuu ggaguacuut t 21
<210> 7
<211> 21
<212> DNA
<213> Artificial sequence
<400> 7
ccuugcugcc aacaaguuut t 21
Claims (9)
1. Regulation and controlINSRRApplication of gene expressed substance in preparing product for regulating and controlling sheep granule cell apoptosis.
2. Use according to claim 1, characterized in that down-regulation is carried outINSRRThe expression quantity of the gene promotes the apoptosis of the sheep granulosa cells.
3. Use according to claim 1 or 2, characterized in that saidINSRRThe gene has a sequence shown as SEQ ID NO. 1.
4. A method of modulating apoptosis in a non-therapeutic sheep granulosa cell comprising down-regulating apoptosis in a sheep granulosa cellINSRRExpression of the gene.
5. The method of claim 4, wherein the down-regulation isINSRRThe expression quantity of the gene promotes the apoptosis of the sheep granulosa cells.
6. The method of claim 5, wherein the downregulating comprises downregulating using siRNAINSRRAnd (4) expressing the gene.
7. The method of claim 6, for down-regulationINSRRThe siRNA expressed by the gene has a sequence shown in SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO. 4.
8. The method of claim 7, for down-regulationINSRRThe siRNA expressed by the gene has a sequence shown in SEQ ID NO. 4.
9. The method of any one of claims 4 to 8, wherein the method is performed in a single cycleINSRRThe gene has a sequence shown as SEQ ID NO. 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010177694.1A CN111334475B (en) | 2020-03-13 | 2020-03-13 | Application of INSRR gene, and product and method for regulating and controlling granulosa cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010177694.1A CN111334475B (en) | 2020-03-13 | 2020-03-13 | Application of INSRR gene, and product and method for regulating and controlling granulosa cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111334475A CN111334475A (en) | 2020-06-26 |
CN111334475B true CN111334475B (en) | 2022-03-01 |
Family
ID=71182596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010177694.1A Expired - Fee Related CN111334475B (en) | 2020-03-13 | 2020-03-13 | Application of INSRR gene, and product and method for regulating and controlling granulosa cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111334475B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109852680B (en) * | 2018-12-25 | 2020-07-03 | 华南农业大学 | Application of FGFR1 gene in porcine ovarian granulosa cells |
CN110129428B (en) * | 2019-05-09 | 2020-12-01 | 安徽农业大学 | Application of miR-26a in regulation of germ cell apoptosis |
CN110106182B (en) * | 2019-05-13 | 2023-01-10 | 华南农业大学 | Application of p65 gene in porcine ovarian granulosa cells |
-
2020
- 2020-03-13 CN CN202010177694.1A patent/CN111334475B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN111334475A (en) | 2020-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | The ontogeny of hepatic growth hormone receptor and insulin-like growth factor I gene expression in the sheep fetus during late gestation: developmental regulation by cortisol | |
Lee et al. | Mouse models of implantation | |
D'Ercole | Insulin-like growth factors and their receptors in growth | |
Yamaji et al. | Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A | |
Hennighausen et al. | Information networks in the mammary gland | |
Shimada et al. | Roles of epidermal growth factor (EGF)-like factor in the ovulation process | |
CN111378663B (en) | lncRNA SFR1, application thereof, and product and method for regulating follicular development | |
Melo et al. | Multitrait meta-analysis identified genomic regions associated with sexual precocity in tropical beef cattle | |
Sferruzzi-Perri | Regulating needs: Exploring the role of insulin-like growth factor-2 signalling in materno-fetal resource allocation | |
Kuradomi et al. | GH overexpression causes muscle hypertrophy independent from local IGF-I in a zebrafish transgenic model | |
Johnson et al. | Expression of epidermal growth factor family gene members in early mouse development | |
Li et al. | BMP4/Smad signaling pathway induces the differentiation of mouse spermatogonial stem cells via upregulation of Sohlh2 | |
Jippo et al. | Abundant expression of transcription factor GATA-2 in proliferating but not in differentiated mast cells in tissues of mice: demonstration by in situ hybridization | |
Hong et al. | TIMP1 may affect goat prolificacy by regulating biological function of granulosa cells | |
Li et al. | A new insertion/deletion fragment polymorphism of inhibin-α gene associated with follicular cysts in Large White sows | |
CN111334475B (en) | Application of INSRR gene, and product and method for regulating and controlling granulosa cells | |
Uri‐Belapolsky et al. | Interleukin 1‐alpha deficiency increases the expression of Follicle‐stimulating hormone receptors in granulosa cells | |
Yuan et al. | Identification of target genes for adenohypophysis-prefer miR-7 and miR-375 in cattle | |
Nogueira et al. | Luteinizing Hormone Receptor (LHR): basic concepts in cattle and other mammals. A review | |
Xiang et al. | In vitro fertilization placenta overgrowth in mice is associated with downregulation of the paternal imprinting gene H19 | |
CN111334476B (en) | Application of HSD17B1 gene and/or NUCB2 gene and regulation and control method of granulosa cells | |
Wei et al. | BMP4/SMAD8 signaling pathway regulated granular cell proliferation to promote follicle development in Wanxi white goose | |
Chaum et al. | Transgenic expression of IGF-1 modifies the proliferative potential of human retinal pigment epithelial cells | |
Yenuganti et al. | The gene expression pattern induced by high plating density in cultured bovine and buffalo granulosa cells might be regulated by specific miRNA species | |
Greene et al. | Use of AgomiR and AntagomiR technologies to alter satellite cell proliferation in vitro, miRNA expression, and muscle fiber hypertrophy in intrauterine growth-restricted lambs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220301 |
|
CF01 | Termination of patent right due to non-payment of annual fee |